Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL trial for bacterial vaginosis pretreatment followed by LC115
PACTR202606582879724Phase 1Not yet recruiting
- Sponsor
- CAPRISA
- Start
- Jul 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LC115, dequalinium and metronidazole in bacterial vaginosis (BV) (3 arms), sponsored by CAPRISA. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
LC115dequaliniummetronidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on PACTR202606582879724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606582879724.